News >

FDA Approves Frontline Obinutuzumab for Follicular Lymphoma

Jason M. Broderick @jasoncology
Published: Thursday, Nov 16, 2017

The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to Genentech, the manufacturer of the therapy.

The FDA previously approved obinutuzumab for use in combination with bendamustine for patients with follicular lymphoma who have received prior therapy.
FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma. https://www.gene.com/media/press-releases/14691/2017-11-16/fda-approves-genentechs-gazyva-for-previ. Accessed November 16, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
x